Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Changchun High-tech: Subsidiary GenSci161's domestically produced injection drug registration clinical trial application has been approved
Changchun High-tech announces that its subsidiary, Jinsai Pharmaceutical, has received approval for the domestic production drug registration clinical trial application for GenSci161 injection.
GenSci161 injection is a Class 1 therapeutic biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of endometriosis and moderate to severe suppurative hidradenitis.